Pfizer 2014 Annual Report Download - page 4

Download and view the complete annual report

Please find page 4 of the 2014 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 75

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75

PFIZER ANNUAL REVIEW 2014 www.pzer.com/annual 4
ANNUAL REVIEW 2014
COLLABORATING TO ACCELERATE INNOVATION
“Over the past few years, CTI has built not only
a strong scientific staff and promising pipeline
but also outstanding collaborations — with
academics, foundations and the NIH — in a
pioneering effort with the goal of speeding up
the drug delivery process.”
JEFFREY A. BLUESTONE, PH.D.
A.W. AND MARY MARGARET CLAUSEN
DISTINGUISHED PROFESSOR
DIRECTOR, HORMONE RESEARCH INSTITUTE
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Pzer’s Centers for Therapeutic Innovation (CTI) is a unique model
for collaboration between academic investigators, patient groups,
the National Institutes of Health and industry, designed to bridge
the gap between early scientic discovery and its translation into
new medicines. With four locations in the biomedical research hubs
of Boston, New York, San Diego and San Francisco, CTI’s open
innovation model puts Pzer scientists in the lab with academic
investigators, where they share their understanding of target biology
and translational medicine expertise. Pzer provides access to select
Pzer molecules, proprietary screening methods, development
technologies, and a wealth of dedicated resources and support from
Pzer experts in drug development and protein sciences.
Pzer funds (or co-funds with patient foundations) pre-clinical and
clinical development programs and offers equitable intellectual
property and ownership rights and access to proprietary technologies.
The ultimate goal of each collaborative project is to create a drug
candidate that can be moved into further clinical testing.
CTI now has more than 25 academic institutions and ve patient
group foundations in its network, with a portfolio of projects across a
variety of disease areas.
TRANSLATING LEADING SCIENCE
INTO CLINICAL CANDIDATES THROUGH
NETWORKED COLLABORATION 25
ACADEMIC
INSTITUTIONS
5
PATIENT GROUP
FOUNDATIONS
CTI HAS MORE THAN
IN ITS NETWORK
Watch the Focus on Lupus – Pzer Centers for Therapeutic
Innovation (CTI) video
DISCOVERIES FOR HEALTHIER LIVES
Homepage > Discoveries for Healthier Lives